Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in *Staphylococcus aureus*

Leon Iri Kupferwasser, … , Ambrose L. Cheung, Arnold S. Bayer


Aspirin has been previously shown to reduce the in vivo virulence of *Staphylococcus aureus* in experimental endocarditis, through antiplatelet and antimicrobial mechanisms. In the present study, salicylic acid, the major in vivo metabolite of aspirin, mitigated two important virulence phenotypes in both clinical and laboratory *S. aureus* strains: α-hemolysin secretion and fibronectin binding in vitro. In addition, salicylic acid reduced the expression of the α-hemolysin gene promoter, *hla*, and the fibronectin gene promoter, *fnbA*. Transcriptional analysis, fluorometry, and flow cytometry revealed evidence of salicylic acid–mediated activation of the stress-response gene *sigB*. Expression of the *sigB*-repressible global regulon *sarA* and the global regulon *agr* were also mitigated by salicylic acid, corresponding to the reduced expression of the *hla* and *fnbA* genes in vitro. Studies in experimental endocarditis confirmed the key roles of both *sarA* and *sigB* in mediating the antistaphylococcal effects of salicylic acid in vivo. Therefore, aspirin has the potential to be an adjuvant therapeutic agent against endovascular infections that result from *S. aureus*, by downmodulating key staphylococcal global regulons and structural genes in vivo, thus abrogating relevant virulence phenotypes.

Find the latest version:

http://jci.me/16876-pdf
Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in *Staphylococcus aureus*

Leon Iri Kupferwasser,1,2 Michael R. Yeaman,1,3 Cynthia C. Nast,3,4 Deborah Kupferwasser,1 Yan-Qiong Xiong,1,3 Marco Palma,5 Ambrose L. Cheung,5 and Arnold S. Bayer1,3

1Division of Infectious Diseases, St. John’s Cardiovascular Research Center and the Research & Education Institute, Harbor-UCLA (University of California–Los Angeles) Medical Center, Torrance, California, USA
2St. Mary Medical Center, Long Beach, California, USA
3UCLA School of Medicine, Los Angeles, California, USA
4Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California, USA
5Department of Microbiology, Dartmouth Medical School, Hanover, New Hampshire, USA

Aspirin has been previously shown to reduce the in vivo virulence of *Staphylococcus aureus* in experimental endocarditis, through antiplatelet and antimicrobial mechanisms. In the present study, salicylic acid, the major in vivo metabolite of aspirin, mitigated two important virulence phenotypes in both clinical and laboratory *S. aureus* strains: α-hemolysin secretion and fibronectin binding in vitro. In addition, salicylic acid reduced the expression of the α-hemolysin gene promoter, *hla*, and the fibronectin gene promoter, *fnbA*. Transcriptional analysis, fluorometry, and flow cytometry revealed evidence of salicylic acid–mediated activation of the stress-response gene *sigB*. Expression of the *sigB*-repressible global regulon *sarA* and the global regulon *agr* were also mitigated by salicylic acid, corresponding to the reduced expression of the *hla* and *fnbA* genes in vitro. Studies in experimental endocarditis confirmed the key roles of both *sarA* and *sigB* in mediating the antistaphylococcal effects of salicylic acid in vivo. Therefore, aspirin has the potential to be an adjuvant therapeutic agent against endovascular infections that result from *S. aureus*, by downmodulating key staphylococcal global regulons and structural genes in vivo, thus abrogating relevant virulence phenotypes.


Received for publication September 10, 2002, and accepted in revised form April 15, 2003.

Address correspondence to: Ambrose L. Cheung, Department of Microbiology, Dartmouth School of Medicine, Hanover, New Hampshire 03755, USA. Phone: (603) 650-1310; Fax: (603) 650-1362; E-mail: ambrose.cheung@dartmouth.edu. Marco Palma’s present address is: Department of Microbiology, Cornell University Medical School, New York, New York, USA.

Conflict of interest: The authors have declared that no conflict of interest exists.

Introduction

*Staphylococcus aureus* is a leading cause of serious systemic infections (e.g., endocarditis, pneumonia, abscesses, septicemia, and osteomyelitis) and often requires hospitalization and intensive antimicrobial therapy (1). The emergence of *S. aureus* resistance to multiple antibiotics, including semisynthetic penicillins, quinolones, and vancomycin, has hastened the need to design more effective antimicrobial regimens (2). Consequently, novel strategies for the therapy of such infections have been sought, including the targeting of known staphylococcal virulence factors for attenuation (3, 4). Delineating compounds that suppress structural or regulatory staphylococcal genes crucial for pathogenesis would potentially accomplish two goals: (a) enhancement of the efficacy of traditional antimicrobial therapy, and (b) reduction in the selective pressure that drives antibiotic resistance (5).

Salicylic acid, the major in vivo metabolite of aspirin, has been demonstrated to interfere with virulence factors at a transcriptional level in several viruses, including the respiratory syncytial virus and HIV-1. Furthermore, in mammalian and plant cells, this compound has been reported to impact intracellular signaling processes and the cytokine network (6, 7). We recently showed that treatment of an invasive experimental *S. aureus* infection (endocarditis) with intravenous aspirin caused a significant reduction in bacterial densities within target tissues (vegetations and kidneys), and that these effects are mediated by salicylic acid (8). We reasoned that salicylic acid may exert a direct effect on bacterial adherins that are necessary for bacterial colonization and propagation in host tissues, or on staphylococcal global regulatory elements such as the staphylococcal accessory regulator, *sarA*, and the accessory gene regulator, *agr*. These two loci also coregulate genes that encode a variety of exoenzymes and exotoxins, including those responsible for cytolysis of host tissues (e.g., the α-hemolysin gene, *hla*) (9, 10).
In this study, we demonstrate that the observed antivirulence properties of aspirin in vivo are based on the direct antimicrobial effects of its metabolite, salicylic acid, and involve activation of the stress-induced transcription factor sigB, leading to repression of the sarA and agr global regulons in S. aureus.

Methods
Bacterial strains, plasmids, and growth media. The bacterial strains and plasmids used in this study are listed in Table 1. These strains were selected to represent a broad range of methicillin-susceptible and methicillin-resistant phenotypes, as well as both clinical and laboratory-derived constructs. All the clinical strains were isolated from patients with serious human infections requiring hospitalization, such as wound infections and endocarditis. Erythromycin (5 µg/ml) and chloramphenicol (10 µg/ml) were used for selection of transformants and transductants in S. aureus, as indicated. Prior to in vitro experiments, S. aureus strains were grown at 37°C in plain tryptic soy broth (control cells) or in medium containing 30 or 50 µg/ml salicylic acid for 18 hours to the late postexponential phase on a rotary shaker. These salicylic acid concentrations encompass readily achievable serum levels observed during therapy of experimental S. aureus endocarditis (11). No impact of salicylic acid on the 24-hour S. aureus growth kinetics was observed at these concentrations (data not shown). In addition, the pH of the bacteria–salicylic acid reaction mixtures did not change as a result of either final concentration of salicylic acid used.

Impact of salicylic acid on S. aureus adherence to fibrinogen and fibronectin. The fibrinogen- and fibronectin-binding capacities of S. aureus strains were evaluated by direct binding of washed bacterial cells (5 × 10^3 CFUs) to solid-phase fibrinogen and fibronectin in six-well plates (9, 10). Plates were coated with 50 µg/ml fibrinogen or fibronectin (Sigma Chemical Co., St. Louis, Missouri, USA), incubated at room temperature for 24 hours, washed three times with PBS, blocked with blocking solution, and washed three more times. Bacterial cells (5 × 10^3 CFUs) were applied to individual wells and incubated for 1 hour at 37°C on a rotating platform. After removal of unbound cells by washing three times with PBS, 2 ml of tryptic soy agar was overlain in all wells. After 24 hours of incubation at 37°C, growth kinetics of the bacteria were observed. The pH of the bacteria–salicylic acid reaction mixtures did not change as a result of either final concentration of salicylic acid used.

Table 1

<table>
<thead>
<tr>
<th>Strain or plasmid</th>
<th>Comment</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S. aureus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RN6390</td>
<td>Laboratory strain related to 8325-4, harboring an 11-bp deletion in rsbU</td>
<td>45</td>
</tr>
<tr>
<td>ALC1001</td>
<td>sigB mutant of RN6390</td>
<td>28</td>
</tr>
<tr>
<td>ALC1497</td>
<td>Complemented sigB mutant of RN6390</td>
<td>28</td>
</tr>
<tr>
<td>SH1000</td>
<td>Functional rsbU derivative of 8325-4, rsbU*</td>
<td>17</td>
</tr>
<tr>
<td>ALC2732</td>
<td>sarA mutant of SH1000</td>
<td>This study</td>
</tr>
<tr>
<td>ALC1435</td>
<td>RN6390 with pALC1420 (gfpuvr with sarA P1 promoter)</td>
<td>22</td>
</tr>
<tr>
<td>ALC1437</td>
<td>RN6390 with pALC1421 (gfpuvr with sarA P2 promoter)</td>
<td>22</td>
</tr>
<tr>
<td>ALC1436</td>
<td>RN6390 with pALC1422 (gfpuvr with sarA P3 promoter)</td>
<td>22</td>
</tr>
<tr>
<td>ALC2200</td>
<td>RN6390 with asp23 promoter driving gfpuvr in pSK236</td>
<td>24</td>
</tr>
<tr>
<td>ALC2270</td>
<td>SH1000 with asp23 promoter driving gfpuvr in pSK236</td>
<td>24</td>
</tr>
<tr>
<td>ALC1540</td>
<td>RN6390 with sarA P3-P1-P2 promoter driving gfpuvr in pSK236</td>
<td>22</td>
</tr>
<tr>
<td>ALC1740</td>
<td>gfpuvr with hla promoter in pSK236 in RN6390</td>
<td>This study</td>
</tr>
<tr>
<td>ALC1747</td>
<td>gfpuvr with fnbA promoter in pSK236 in RN6390</td>
<td>This study</td>
</tr>
<tr>
<td>ALC1737</td>
<td>gfpuvr with fnbB promoter in pSK236 in RN6390</td>
<td>This study</td>
</tr>
<tr>
<td>ALC1741</td>
<td>gfpuvr with spa promoter in pSK236 in RN6390</td>
<td>This study</td>
</tr>
<tr>
<td>ALC1742</td>
<td>gfpuvr with agr RNAIII promoter in pSK236 in RN6390</td>
<td>This study</td>
</tr>
<tr>
<td>ALC1743</td>
<td>sarA mutant of RN6390</td>
<td>48</td>
</tr>
<tr>
<td>ALC2322</td>
<td>FDA486 with asp23 promoter driving gfpuvr in pSK236</td>
<td>This study</td>
</tr>
<tr>
<td>COL</td>
<td>Methicillin-resistant laboratory strain</td>
<td>49</td>
</tr>
<tr>
<td>RUSA168</td>
<td>sigB mutant of COL</td>
<td>49</td>
</tr>
<tr>
<td>ISP479C</td>
<td>Spontaneous plasmid-cured derivative of parental strain ISP479</td>
<td>50</td>
</tr>
<tr>
<td>6850</td>
<td>Clinically isolated wild-type strain</td>
<td>51</td>
</tr>
<tr>
<td>Newman</td>
<td>Laboratory strain</td>
<td>52</td>
</tr>
<tr>
<td>MRSA 67-0</td>
<td>Wound isolate</td>
<td>53</td>
</tr>
<tr>
<td>Duke strains 28, 153, 237</td>
<td>Isolates from patients with infective endocarditis</td>
<td>54</td>
</tr>
<tr>
<td><strong>Plasmids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pSK236</td>
<td>Shuttle vector containing pUC19 cloned into the HindIII site of pC194</td>
<td>52</td>
</tr>
<tr>
<td>pALC1420</td>
<td>pSK236 containing gfpuvr preceded by the 240-bp sarA P1 promoter fragment</td>
<td>17</td>
</tr>
<tr>
<td>pALC1421</td>
<td>pSK236 containing gfpuvr preceded by the 162-bp sarA P3 promoter fragment</td>
<td>17</td>
</tr>
<tr>
<td>pALC1422</td>
<td>pSK236 containing gfpuvr preceded by the 382-bp sarA P2 promoter fragment</td>
<td>17</td>
</tr>
</tbody>
</table>

The Journal of Clinical Investigation | July 2003 | Volume 112 | Number 2 223
visible colonies were counted. As the binding patterns of the clinical and laboratory isolates were virtually identical, data were pooled within each isolate group, and bacterial binding was quantified as the percentage of the initial inoculum bound; the impact of salicylic acid exposure on binding was expressed as the mean reduction (± SD) of fibrinogen or fibronectin binding when compared with that of control cells unexposed to salicylic acid, from six separate runs.

Bacterial cells were pre-exposed to 6 mM sodium azide for 60 minutes at room temperature after overnight culture in the absence and presence of salicylic acid; then binding experiments were repeated to ascertain the requirement for an energy-dependent process.

To evaluate whether the effects of salicylic acid on S. aureus binding to fibrinogen and fibronectin are mediated via the upregulation of a serine protease (which cleaves and degrades such adhesins), we performed the fibronectin-binding experiments in parallel with cultures pre-exposed to 0.4 U of the global protease inhibitor α2-macroglobulin (12).

The sarA operon positively regulates the expression of a number of adhesin genes (13, 14), while the global stress regulon sigB negatively regulates the function of several adhesin genes (via repression of sarA gene expression; refs. 15, 16). To determine whether sigB is involved in salicylic acid–mediated effects on S. aureus binding to fibrinogen and fibronectin, we evaluated fibrinogen and fibronectin binding in vitro in the following constructs: parental strain COL; its respective sigB deletion mutant; parental strain RN6390; its respective sigB deletion mutant; and its sigB-complemented strain. To explore the role of rsbU within the sigB operon, we also compared the salicylic acid–mediated effects on adhesin binding of RN6390, which carries a natural rsbU deletion, with those of SH1000, a derivative of RN6390 that carries a functional rsbU gene (17). To determine whether the sarA operon is involved in S. aureus binding to the above adhesion molecules, salicylic acid–mediated effects on S. aureus binding to fibrinogen and fibronectin were evaluated in sarA knockout mutants of RN6390 and SH1000.

**Impact of salicylic acid on hemolytic and thrombolytic (platelet lysis) activity of S. aureus.** In addition to matrix protein binding, the secretion of exotoxins, such as α-hemolysin, represents a major virulence factor in staphylococcal pathogenesis by virtue of its cytolytic effect on many types of host cells (18). We thus evaluated whether salicylic acid would impact α-hemolysin activity in S. aureus, using two distinct target cells for this enzyme, rabbit erythrocytes and rabbit platelets.

For hemolytic studies, cells in each tube were washed, equalized at OD600, and centrifuged at 5,000 g for 10 minutes to pellet bacteria. Aliquots of serial dilutions of culture supernatants were added to a 1% suspension of washed rabbit erythrocytes in 0.01 M PBS (pH 7.2) containing 0.1% BSA (19). Purified α-hemolysin (1 µg/ml; kindly provided by Barbara E. Menzies, Vanderbilt University, Nashville, Tennessee, USA) was used as a positive control. Since supernatants of both the parental clinical and laboratory S. aureus strains yielded virtually identical hemolytic activity, pooled data for each isolate group were expressed as mean units of hemolytic activity (± SD) of all parental strains per milliliter of culture supernatant from six separate runs. The hemolytic units were defined as the reciprocal of the highest dilution of the culture supernatant that caused 50% hemolysis as measured by optical densitometry (19).

For the thrombolytic studies, washed platelets were suspended in Tyrode’s medium and adjusted to an OD600 of 1.0 (equal to approximately 10⁸ platelets/ml). Platelets were then exposed to serial dilutions of culture supernatants. Thrombolysis was monitored by measurement of the fall in OD600 over 30 minutes (19).

Purified α-hemolysin and the membrane detergent Triton X-100 (0.1%) were used as positive thrombolysis controls. Exposure of rabbit platelets to Triton X-100 or purified α-hemolysin resulted in 100% lysis (i.e., decrease in the OD600 of the platelet suspension from 1.0 to base line) within 30 minutes. Thrombolytic activity was expressed as the mean fall of OD600 (± SD) as normalized to Triton X-100 from six separate runs.

**Impact of salicylic acid on α-hemolysin production.** As a complement to the above functional assays for α-hemolysin, we studied the impact of salicylic acid on the specific production of this toxin. Culture supernatants from equal numbers of S. aureus parental cells Newman and RN6390, and the relevant sigB deletion and sigB-complemented variants, pre cultured in the absence or presence of salicylic acid, were diluted and applied to a 12% SDS-polyacrylamide gel for α-hemolysin detection by immunoblot. The gel proteins were electrophoretically transferred to nitrocellulose membranes. After the membranes were blotted, they were blocked with 0.5% Tween-20 in Tris-buffered saline, and then incubated for 1 hour with rabbit polyclonal anti-α-hemolysin serum (1:100 dilution). The blot was developed with goat anti-rabbit IgG–alkaline phosphatase conjugate (Molecular Probes Inc., Eugene, Oregon, USA) at a 1:2,000 dilution using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as the substrate (20).

**Impact of salicylic acid on protease and lipase production.** We evaluated the effects of salicylic acid on lipase and protease secretion, two sarA-repressible phenotypes, by spectrophotometric assays in postexponential culture supernatants of the parental study strains, Newman, RN6390, COL, and ISP479C, as well as in the sigB mutant and sigB-complemented variant of RN6390, in the presence or absence of salicylic acid (50 µg/ml).

For quantification of global protease activity, the azocasein spectrophotometric hydrolysis assay was used. After equalizing all cultures at OD600, 300 µl of culture supernatants were added to 800 µl of an azocasein solution and incubated for 16 hours at 37°C. Undegraded azocasein was precipitated by the addition of 400 µl of 50% trichloroacetic acid and removed.
by centrifugation. Protease activity was indicated by clearing of the supernatant solution with a concomitant decrease in OD$_{400}$ (21).

For quantification of lipase activity, a tributyrin assay was used, as previously described (21). In brief, 1 ml of the prewarmed tributyrin emulsion (50°C) was added to 100 µl of each standardized culture supernatant. The OD was monitored at 450 nm at room temperature. Lipase activity was indicated by a clearing of the emulsion and quantified by a subsequent decrease in OD.

As the protease and lipase activities of parental S. aureus cells were virtually identical, data were pooled, and the impact of salicylic acid was expressed as the result of six separate runs based on the normalized OD of cells grown in the absence of salicylic acid.

**Whole-cell ELISA for detection of cell wall–associated protein A.** To determine levels of protein A production (a sarA-repressible phenotype), cell wall–associated proteins were extracted from overnight cultures of strain Newman and of strain RN6390, its sigB mutant, and its sigB-complemented strain, using lysostaphin in a hypertonic medium (30% raffinose). Microtiter wells were coated with human IgG at 1 µg/ml overnight at 37°C. Serial dilutions of extracts of cell wall proteins in 1x PBS, 0.05% Tween-20, and a control protein A standard (Calbiochem Corp., San Diego, California, USA) were added to microtiter wells, then probed with affinity-purified chicken anti–protein A antibody (Accurate Chemical & Scientific Group., Westbury, New York, USA) at a 1:3,000 dilution. Bound antibody was detected by immune colorimetry with rabbit anti-chicken IgG (1:5,000 dilution) conjugated to alkaline phosphatase (Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania, USA), using p-nitrophenyl phosphate as a developing substrate. Microtiter wells were then read in an ELISA plate reader (Bio-Tek Instruments Inc., Winooski, Vermont, USA) and expressed as the average of two runs.

**Impact of salicylic acid on promoter gene expression in vitro and in vivo.** To define whether salicylic acid–induced changes in S. aureus binding to matrix proteins, and α-hemolysin production, were attributable to impacts on virulence gene expression, we employed a gene reporter system. We used a shuttle plasmid with a promoter (a sigB-dependent locus, and a surrogate for sigB promoter activation; ref. 24). The GFP excitation maximum in these constructs has been shifted from 395 to 488 nm by a single substitution at residue 65 (serine to threonine [S65T]), yielding GFP$m^{	ext{av}}$ (22, 23). GFP fluorescence was detected by excitation at 488 nm and emission at 520 nm. Fluorometry (Turner Fluorometer model 450; Barnstead International, Dubuque, Iowa, USA) or flow cytometry (FACSCalibur; Becton Dickinson Biosciences, Sparks, Maryland, USA) was conducted on equal concentrations of bacterial cells to quantitate in vitro expression of GFP. Results were expressed as the average of three separate runs. Fluorescence microscopy (Olympus America Inc., Melville, New York, USA) was used to detect the impact of acetylsalicylic acid or salicylic acid on in vivo expression of GFP in cells within vegetative lesions removed from rabbits with infective endocarditis (22). The slides were also stained with Giemsa stain for localization of bacteria within the vegetations. In addition, to provide a more quantitative assessment of in vivo gene expression, 10,000 intravegetation staphylococcal cells from control or aspirin-treated rabbits were evaluated for sarA P1 GFP fluorescence by flow cytometry as previously described (25).

**Impact of salicylic acid on sarA gene transcription by Northern analysis.** For staphylococcal RNA extraction, 10-ml cultures of S. aureus RN6390 and Newman were grown to mid–log phase (OD$_{650}$, 0.7), late log phase (OD$_{650}$, 1.1), and postexponential phase (OD$_{650}$, 1.7), pelleted by centrifugation, resuspended in FastRNA reagent (Qbiogene Inc., Carlsbad, California, USA) in combination with 0.1-mm Zirconia-silica beads, and shaken at 6,000 rpm in a high-speed homogenizer for 20 seconds. After addition of 200 µl chloroform, the sample was centrifuged at 12,000 g at 4°C for 10 minutes. The RNA located in the upper aqueous layer was precipitated with isopropanol and resuspended in water treated with Diethyl pyrocarbonate. The integrity of the RNA species was verified with a formamide gel (26). Ten micrograms of RNA from each culture condition was electrophoresed through a 1.5% agarose, 0.66 M formamide gel in Mops running buffer (26). RNA was blotted onto Hybond N’ membranes (Amersham Biosciences Corp., Piscataway, New Jersey, USA) using a TurboBlotter alkaline transfer system (Schleicher & Schuell Inc., Keene, New Hampshire, USA). For detection of sarA transcripts, gel-purified DNA probes were radiolabeled with $[^{32}$P]dCTP by the random-primer method, and hybridized under high-stringency conditions. The blots were subsequently washed and autoradiographed (27).

**Impact of salicylic acid on SarA protein production.** S. aureus strain SH1000, carrying an intact sigB operon, was diluted 1:100 from an overnight culture into 50 ml of tryptic soy broth containing 50 µg/ml of salicylic acid; the control culture did not contain any salicylic acid. Both cultures grew to similar OD and were harvested 8 hours later (the time of maximal SarA protein expression). Cell-free extracts of each culture were prepared as described (28). The protein concentration of each preparation was determined by the Bradford assay (Bio-Rad Laboratories Inc., Hercules, California, USA). Equivalent amounts of cell-free extract of each cell preparation were then loaded onto a 12% SDS gel, resolved, and blotted
Hemolytic and thrombolytic activity of laboratory or clinical isolates to fibrinogen or fibronectin ranged from 7.1% to 10.2% of the inoculum. The reductions in matrix protein binding and lysis represent composite pooled data derived from the laboratory S. aureus strains RN6390, COL, Newman, and ISP479C, and the clinical S. aureus isolates MRSA 67-0, 6850, Duke 28, Duke 153, and Duke 237. SAL, salicylic acid. \( ^{a}P < 0.002, ^{b}P < 0.001 \).

### Results

**In vitro effect of salicylic acid on S. aureus virulence phenotypes upregulated by sarA.** Parental S. aureus cells preincubated in the presence of salicylic acid demonstrated a substantial, dose-dependent reduction in binding to both fibronectin and fibrinogen, at two clinically achievable serum concentrations (Table 2). The mitigating effects of salicylic acid on S. aureus binding to these matrix proteins were virtually eliminated when the organism was preexposed to sodium azide, an inhibitor of oxidative phosphorylation (data not shown); this emphasized the requirement for an energy-dependent process in viable bacteria to fully execute this salicylic acid-mediated effect. Similar to the extent of binding, the extents of hemolysis and thrombolysis, presumably mediated by \( \alpha \)-hemolysin in supernatants obtained from cells preincubated in the presence of salicylic acid, were significantly less than observed with control cells. The extent of mitigation of matrix protein binding and target cell cytolysis was very similar between clinical and laboratory strains. The in vitro hemolytic, thrombolytic (platelet lysis), and matrix protein-binding assays were repeated with two other clinically available NSAIDs, aspirin (the parent compound of salicylic acid) and indomethacin. Neither of these agents yielded any substantial impact on the cytolytic or matrix-binding phenotypes in parental strains RN6390, COL, or Newman (data not shown). Thus, there was a relative specificity of salicylic acid as compared with several clinically used NSAIDs in regard to the above impacts on the S. aureus phenotypes examined. More importantly, these data substantiated the requirement of the conversion of acetylsalicylic acid to salicylic acid for its in vitro antimicrobial properties.

**In vitro effect of salicylic acid on S. aureus phenotypic and genotypic parameters downregulated by sarA.** The downregulation in the expression of fibronectin-binding proteins and \( \alpha \)-hemolysin due to salicylic acid is consistent with a downregulation in SarA-mediated effects. To assess other phenotypes that might be upregulated in S. aureus as a result of diminished SarA expression, we examined

<table>
<thead>
<tr>
<th>Laboratory isolates</th>
<th>Clinical isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAL, 30 µg/ml</td>
<td>SAL, 50 µg/ml</td>
</tr>
<tr>
<td>Fibronecit binding</td>
<td>-35.9% ± 6.5%(^{a})</td>
</tr>
<tr>
<td>Fibrinogen binding</td>
<td>-35.4% ± 5.2%(^{a})</td>
</tr>
<tr>
<td>Hemolysis</td>
<td>-48% ± 4%(^{b})</td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>-32% ± 4%(^{a})</td>
</tr>
</tbody>
</table>

Numbers listed in the table indicate the mean reduction (± SD) as compared with controls (S. aureus preincubated in plain medium) used as the standard (i.e., 100%). Binding of S. aureus control cells (laboratory or clinical isolates) to fibronectin or fibrinogen ranged from 7.1% to 10.2% of the inoculum. Hemolytic and thrombolytic activity of S. aureus control cells ranged from 550 to 800 hemolytic units and from 56% to 84%, respectively. The reductions in matrix protein binding and lysis represent composite pooled data derived from the laboratory S. aureus strains RN6390, COL, Newman, and ISP479C, and the clinical S. aureus isolates MRSA 67-0, 6850, Duke 28, Duke 153, and Duke 237. SAL, salicylic acid. \( ^{a}P < 0.002, ^{b}P < 0.001 \).

**Statistics.** For in vitro experiments, the one-way Kruskal-Wallis ANOVA test and the Dunn’s posthoc comparison were used to compare data sets generated for S. aureus cells preincubated in salicylic acid (30 or 50 µg/ml) with those for untreated control cells. When control cells were compared with cells preincubated in a single dose of salicylic acid, the two-sided Mann-Whitney \( U \) test was used. For in vivo experiments, the two-sided Mann-Whitney \( U \) test was used to compare data sets generated in salicylic acid–treated and untreated animals. A \( P \) value \( \leq 0.05 \) was considered significant.

**Rabbit endocarditis model.** To evaluate the in vivo role of the sarA and the sigB operons in mediating the antimicrobial effects of salicylic acid, we induced endocarditis in rabbits with the parental strain RN6390 and its rsbU-repaired derivative SH1000; the parental strain COL; the respective sigB and sarA mutants; and the sigB-complemented variant of RN6390. In brief, anesthetized rabbits (New Zealand white; Irish Farms, Corona, California, USA) underwent transcatheter-transaortic valve catheterization with a polyethylene catheter to induce sterile aortic valve vegetations. The catheter remained indwelling for the duration of this study. Animals were challenged intravenously with the ID\(_{50}\) inoculum of the study S. aureus strains (as established by pilot studies) at 24 hours after catheterization. Oral treatment (by gavage) with 8 mg/kg/d salicylic acid or intravenous treatment with 8 mg/kg/d acetylsalicylic acid (Bayer AG, Leverkusen, Germany) was initiated at 24 hours after infection, over the next 72 hours. This dose was previously established (8) to exert maximal antimicrobial effects against S. aureus in this model. At 96 hours after infection, animals were euthanized with a rapid intravenous injection of 100 mg/kg sodium pentobarbitral (Abbott Laboratories, Chicago, Illinois, USA). During autopsy, vegetations and kidneys were removed to determine vegetation weights, as well as bacterial densities in vegetations and kidney lesions (8). In addition, vegetations were processed for in vivo fluorescence microscopy as previously described (22). All rabbits were treated in accordance with institutional and US Public Health Service guidelines for the humane care and treatment of animals.

**Table 2**

| Effect of salicylic acid on fibronectin and fibrinogen binding, hemolysis, and thrombolysis of laboratory S. aureus strains and clinical S. aureus isolates
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory isolates</td>
<td>Clinical isolates</td>
</tr>
<tr>
<td>Fibronecit binding</td>
<td>-35.9% ± 6.5%(^{a})</td>
</tr>
<tr>
<td>Fibrinogen binding</td>
<td>-35.4% ± 5.2%(^{a})</td>
</tr>
<tr>
<td>Hemolysis</td>
<td>-48% ± 4%(^{b})</td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>-32% ± 4%(^{a})</td>
</tr>
</tbody>
</table>

\( ^{a}P < 0.002, ^{b}P < 0.001 \).
Table 3
Effect of 50 µg/ml salicylic acid on fibronectin and fibrinogen binding, hemolysis, and thrombolysis of the S. aureus strains listed

<table>
<thead>
<tr>
<th></th>
<th>RN6390 parent</th>
<th>RN6390 sarA+ mutant</th>
<th>SH1000 rsbU+ derivative</th>
<th>SH1000 sarA- mutant</th>
<th>RN6390 sigB+ mutant</th>
<th>RN6390 sigB compl.</th>
<th>COL parent</th>
<th>COL sigB mutant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibronectin binding</td>
<td>-54.6 ± 7.3A</td>
<td>-51.5 ± 2A</td>
<td>-40.8 ± 3.6A</td>
<td>-7.2 ± 0.4</td>
<td>-8.6 ± 2.6</td>
<td>-49.7 ± 6.2A</td>
<td>-51.6 ± 6.1A</td>
<td>-5.6 ± 0.7</td>
</tr>
<tr>
<td>Fibrinogen binding</td>
<td>-51.6 ± 5.2A</td>
<td>-11.16 ± 4.1</td>
<td>-45.6 ± 3.7A</td>
<td>-12.6 ± 0.8</td>
<td>-7.1 ± 2.2</td>
<td>-51.2 ± 6.5A</td>
<td>-51.2 ± 6.9A</td>
<td>-6.6 ± 1.0</td>
</tr>
<tr>
<td>Hemolysis</td>
<td>-64 ± 8A</td>
<td>-9 ± 2</td>
<td>-51 ± 5A</td>
<td>-10 ± 14</td>
<td>-4 ± 1</td>
<td>-56 ± 9A</td>
<td>-56 ± 9A</td>
<td>-7 ± 1</td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>-58 ± 7A</td>
<td>-13 ± 2</td>
<td>-45 ± 6A</td>
<td>-6 ± 4</td>
<td>-3 ± 1</td>
<td>-53 ± 6A</td>
<td>-49 ± 4A</td>
<td>-2 ± 1</td>
</tr>
</tbody>
</table>

The background of each strain is indicated next to the mutant type. Numbers indicate the percent mean reduction (± SD) as compared with controls (S. aureus precultured in plain medium). Compl., complemented. *P < 0.003.

protease and lipase activities. Protease and lipase activities were elevated in supernatants from parental S. aureus strains exposed to salicylic acid: protease activity was increased fivefold (P < 0.0001) and lipase activity was increased 2.6-fold (P < 0.0001) in supernatants from salicylic acid–treated cells versus untreated controls. The salicylic acid–induced increase of protease activity was blunted in cells precultured in the presence of the global protease inhibitor α2-macroglobulin. However, 50 µg/ml salicylic acid caused similar and significant reductions in fibronectin binding of the above parental strains in the presence or absence of pre-exposure to α2-macroglobulin (45.7% ± 4.2% vs. 53.9% ± 5.5% reductions, respectively; P < 0.0001). These findings provide evidence that the salicylic acid–induced suppression of the S. aureus fibronectin-binding phenotype is not principally related to an increase in protease secretion that leads to adhesin inactivation (12).

A mean increase of 17.6% ± 3.9% in protein A levels versus untreated controls was observed in parental S. aureus strains exposed to 50 µg/ml salicylic acid. In parallel, a corresponding twofold increase in spa promoter expression was noted in salicylic acid–treated cells as compared with untreated controls, suggesting a salicylic acid–mediated impact on the structural gene and/or the respective regulator gene.

The role of sarA and sigB in salicylic acid–mediated modifications of S. aureus phenotypes. In sarA mutants of strain RN6390 and its isogenic rsbU-repaired derivative SH1000, intrinsic binding to fibrinogen and fibronectin was reduced with compared with that in the corresponding parental strains (fibrinogen, 19.4% ± 3.1%; fibronectin, 22.7% ± 2.6%). Hemolysis and thrombolysis in these sigB knockouts were increased by 14.6% ± 5.7% and 17.5% ± 4.4%, respectively, when compared with those in the parental strains. Salicylic acid–mediated reductions in matrix protein binding, hemolysis, and thrombolysis observed in these parental strains were mitigated in the respective sigB knockouts (Table 3). Moreover, no impact of salicylic acid on protease-activity or lipase-activity profiles or cell wall protein A production was detectable in the sigB knockout of RN6390. These phenotypic response parameters were restored to parental levels with complementation of sigB in the RN6390 background. Notably, salicylic acid caused similar extents of reduction in matrix protein binding and cytolytic profiles in parental strain RN6390 and its rsbU-repaired derivative SH1000 (Table 3).

In summary, the above observations suggest that in parental S. aureus strains, salicylic acid suppresses exotoxin production and matrix protein binding, while enhancing exoenzyme (e.g., protease and lipase) and protein A production. The presence of an intact sarA locus and the sigB stress operon (with or without a functional rsbU locus) appears to be a prerequisite in this context. Therefore, this composite phenotype is consistent with suppression of sarA expression following sigB activation in either an rsbU-dependent or an rsbU-independent manner (13–16).

Figure 1
Western blot for detection of α-hemolysin. An immunoblot of culture supernatants of the indicated S. aureus strains precultured in the absence (controls) or presence of 30 and 50 µg/ml salicylic acid to the early stationary phase (18 hours) was probed for α-hemolysin. Affinity-purified rabbit polyclonal anti-α-hemolysin IgG was used as the primary antibody. SAL, salicylic acid.
α-Hemolysin production. Paralleling the hemolytic and thrombolytic data sets above, α-hemolysin was detected by immunoblots in supernatants of parental S. aureus strains grown in the absence of salicylic acid but was substantially diminished in the presence of salicylic acid (Figure 1). Immunoblots of extracellular proteins derived from supernatants of postexponential-phase cultures of the RN6390 parent, its sigB mutant, and its sigB-complemented variant grown in salicylic acid disclosed a substantial reduction in α-hemolysin production in the parental and sigB-complemented strains, as compared with little impact on α-hemolysin production in the sigB deletion mutant (Figure 2). These data, combined with the phenotypic findings above, clearly support the notion that the sigB operon is pivotal in mediating the antimicrobial effects of salicylic acid in vitro in the context of cytolysis.

Salicylic acid–induced impacts on hla, fnbA, and fnbB promoter expression in vitro. In parental strain RN6390, fluorometric analyses revealed a 2.9-fold and a 2.1-fold decrease, respectively, in fnbA and fnbB promoter expression in cells treated with 50 µg/ml salicylic acid, as compared with untreated controls. Similarly, there was a 3.3-fold reduction in hla promoter expression in salicylic acid–treated cells, compared with untreated control cells. These data demonstrate that the mitigating effects of salicylic acid on staphylococcal fibronectin binding and on α-hemolysin production were correlated with reduced transcription of the relevant gene promoters in S. aureus.

Salicylic acid–induced impacts on sarA and agr promoter expression and sigB gene expression in vitro. By fluorometric analysis, treatment of S. aureus RN6390 with 50 µg/ml salicylic acid caused (a) a 2.3-fold reduction in the expression of the sarA P1 promoter, the strongest promoter within the triple-sarA-promoter system; (b) a 1.8-fold reduction in the native triple-sarA-promoter complex (i.e., sarA P2-P3-P1); and (c) a 2.0-fold and a 2.2-fold reduction in agr RNAII and agr RNAIII promoter expression, respectively, as compared with those in untreated controls.

With respect to the sarA operon, we independently confirmed the above fluorometric data by both flow cytometry and Northern analysis. There are three promoters (P2, P3, and P1) upstream of the sarA coding region, with the proximal P1 promoter being the strongest. Flow cytometry revealed a 2.5-fold decrease in P1-initiated sarA transcription in the presence of salicylic acid, whereas the activity of the middle sarA promoter, P3, which is sigB-dependent, was twofold higher in salicylic acid–treated than in untreated cells (Figure 3a). Consistent with the flow cytometry data sets, Northern analysis of strains RN6390 (Figure 3b) and Newman (not shown).
demonstrated that the sarA P3 transcript level was increased in cells pre-exposed to salicylic acid when compared with untreated cells, while the sarA P1 transcript level was decreased compared with that in untreated cells.

The upregulation of the sarA P3 transcript in response to salicylic acid further suggested a salicylic acid–induced upregulation of sigB. Therefore, we used fluorometry to analyze the impact of salicylic acid on expression of a major sigB-dependent promoter, asp23, in three S. aureus strains with two distinct backgrounds: (a) RN6390, carrying a natural rsbU deletion within the sigB operon; (b) SH1000, the functional rsbU derivative of RN6390; and (c) FDA486, carrying an intact sigB operon. In these strains, salicylic acid caused a 1.5- to 1.9-fold increase in asp23 promoter expression as compared with that in untreated cells. Collectively, these data demonstrate a net salicylic acid–mediated downmodulation of both the sarA and the agr operons, associated with an upregulation of sigB, which occurred in both the presence and the absence of an intact rsbU locus within the sigB operon.

Expression of SarA protein in S. aureus strain SH1000 upon exposure to salicylic acid. To determine whether a change in SarA protein level occurred in strain SH1000 (with an intact sigB locus) when it was exposed to salicylic acid, we probed an immunoblot containing equivalent amounts of early stationary-phase cell extracts of strain SH1000, precultured in the presence and absence of salicylic acid, with an anti-SarA mAb. At 50 µg of cellular proteins, there was a 10% reduction in SarA protein levels in cells precultured in salicylic acid at 50 µg/ml (516 vs. 576 densitometric units in treated and untreated cells, respectively).

The role of the sarA locus in salicylic acid–mediated effects in vivo. Aortic-catheterized rabbits were challenged intravenously with either parental strain RN6390 or its isogenic sarA knockout mutant. Rabbits treated with 8 mg/kg/d salicylic acid and infected with parental strain RN6390 demonstrated significantly smaller vegetations and lower bacterial densities in vegetations and kidney lesions than did their respective untreated controls; these effects were substantially blunted in salicylic acid–treated rabbits challenged with the sarA knockout mutant (Table 4). Thus, the sarA locus plays a predominant role in mediating the in vivo effects of salicylic acid, paralleling the in vitro data above.

To further substantiate the in vivo downmodulatory impact of salicylic acid on sarA expression, aortic-catheterized rabbits and infected with the S. aureus RN6390 sarA P1 gfpuvr construct either went untreated or received 8 mg/kg/d aspirin intravenously. While bacterial cells in vegetations from control animals demonstrated a high level of in situ GFP fluorescence, cells from aspirin-treated rabbits showed a substantial reduction in GFP fluorescence, indicative of reduced sarA P1 expression in the presence of salicylic acid in vivo.

**Table 4**

Effect of salicylic acid on microbial proliferation and hematogenous dissemination in rabbits with infective endocarditis challenged with parental strain RN6390 or its sarA mutant

<table>
<thead>
<tr>
<th>Strains</th>
<th>Number of animals</th>
<th>Vegetation weight (g)</th>
<th>Vegetation bacterial density (log_{10} CFUs/g tissue)</th>
<th>Renal bacterial density (log_{10} CFUs/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control Treatment</td>
<td>Control Treatment</td>
<td>Control Treatment</td>
<td>Control Treatment</td>
</tr>
<tr>
<td>RN6390</td>
<td>8</td>
<td>0.12 ± 0.01</td>
<td>8.32 ± 0.93</td>
<td>8.41 ± 0.88</td>
</tr>
<tr>
<td>sarA mutant</td>
<td>7</td>
<td>0.12 ± 0.01</td>
<td>7.56 ± 0.63</td>
<td>7.49 ± 0.65</td>
</tr>
</tbody>
</table>

In vivo plasma levels of salicylic acid were evaluated in the treatment groups by an immunoassay and were 51 ± 2.9 µg/ml (47–55 µg/ml). *Mean mortality rate 13.9% (range 11.1–22.2%). Mean mortality rate without significant differences between groups. *P < 0.007 vs. control.

**Figure 4**

Fluorescence analysis of aspirin-induced effects on sarA P1 gfpuvr constructs in vivo. Vegetative lesions were removed from rabbits with infective endocarditis 24 hours after they received no treatment (controls) or a single intravenous dose of 8 mg/kg aspirin, and fluorescence microscopy was conducted on sarA P1 gfpuvr constructs within the lesions. In vegetations from control rabbits, bright green fluorescence (a) can be clearly detected as originating from the respective cells shown in the adjacent section stained with Giemsa (b). In comparison, the fluorescence intensities of individual bacterial cells found in Giemsa-stained vegetation sections of aspirin-treated rabbits (d) show a marked reduction in fluorescence (c, arrowheads), even at the highest immunofluorescent microscopy gain (magnification ×350).
Table 5
Effect of salicylic acid on microbial proliferation in vegetative lesions and hematogenous dissemination to kidneys of rabbits with experimental endocarditis due to the S. aureus strains listed

<table>
<thead>
<tr>
<th>Strains</th>
<th>Number of animals&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Vegetation weight (g)</th>
<th>Vegetation bacterial density (log&lt;sub&gt;10&lt;/sub&gt; CFUs/g tissue)</th>
<th>Renal bacterial density (log&lt;sub&gt;10&lt;/sub&gt; CFUs/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Treatment</td>
<td>Control</td>
<td>Treatment</td>
</tr>
<tr>
<td>RN6390</td>
<td>7</td>
<td>6</td>
<td>0.12 ± 0.01</td>
<td>0.07 ± 0.01&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>sigB mutant (RN6390)</td>
<td>6</td>
<td>6</td>
<td>0.13 ± 0.01</td>
<td>0.12 ± 0.01&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>sigB complemented (RN6390)</td>
<td>6</td>
<td>6</td>
<td>0.11 ± 0.01</td>
<td>0.06 ± 0.01&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>SH1000</td>
<td>5</td>
<td>5</td>
<td>0.25 ± 0.07</td>
<td>0.18 ± 0.06&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>COL</td>
<td>7</td>
<td>7</td>
<td>0.17 ± 0.09</td>
<td>0.05 ± 0.02&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>sigB mutant (COL)</td>
<td>6</td>
<td>7</td>
<td>0.13 ± 0.04</td>
<td>0.12 ± 0.06&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Each respective background strain is indicated next to the mutant. In vivo plasma levels of salicylic acid were evaluated in the treatment groups by an immunoassay and were 49 ± 2.4 µg/ml (46–57 µg/ml). <sup>a</sup>Mean mortality rate 8.4% (range 0–14.3%). Mean mortality rate without significant differences between groups.

<sup>b</sup>P < 0.002 vs. control group; <sup>c</sup>P < 0.01 vs. control group; <sup>d</sup>P < 0.03 vs. control group; <sup>e</sup>P < 0.05 vs. control group.

(Figure 4). These observations were quantitatively confirmed via flow cytometry by the substantially reduced sarA P1 promoter–driven GFP expression among 10,000 staphylococcal cells isolated from aspirin-treated versus control vegetations (data not shown).

The role of the sigB operon in salicylic acid–mediated effects in vivo. In rabbits catheterized in the aorta and infected with parental S. aureus strain RN6390 or COL or the RN6390 sigB-complemented mutant, salicylic acid therapy yielded significant reductions in vegetation weight, as well as in vegetation and kidney bacterial densities, as compared with their respective untreated controls. In contrast, in rabbits infected with the sigB deletion mutants of either RN6390 or COL, salicylic acid treatment did not yield any significant effects on these parameters (Table 5). The salutary effects of salicylic acid therapy in animals infected with parental strain RN6390 were closely paralleled in salicylic acid–treated animals infected with its rsbU-repaired derivative SH1000 (Table 5). Taken together, these data further confirmed the integral role of the sigB operon in mediating the antimicrobial effects of salicylic acid in vivo.

Discussion

Over the past decade, a number of investigations have demonstrated that acetylsalicylic acid and/or its predominant metabolite, salicylic acid, exhibit definable impacts both in vitro and in vivo on microbial virulence phenotypes. The following effects have been noted: reduction of adhesion to relevant biomatrices (29), reduction of capsule production (30), mitigation of biofilm formation (31), and diminution of vegetation growth, intravascular bacterial proliferation, and hematogenous dissemination in experimental infectious endocarditis (32). Salicylic acid also has been shown to upregulate the translation of specific gene loci, including multiple antibiotic-resistance loci (33); to induce cytoplasmic proteins (34); and to increase quinolone resistance (35). We recently studied the potential antimicrobial mechanisms of aspirin in the infective endocarditis model (8) and demonstrated that salicylic acid was the principal mediator of these antimicrobial effects in vivo. The present study was designed to further characterize the in vitro and in vivo impact of salicylic acid, particularly focusing on potential microbial genetic pathways involved in these effects, in the context of experimental infective endocarditis.

We demonstrated that, at levels achievable in human serum (11), salicylic acid mitigated two distinct virulence phenotypes that are of key relevance in the pathogenesis of experimental infective endocarditis: matrix protein binding (i.e., to fibrinogen and fibronectin) and α-hemolysin activity. These effects were specifically associated with salicylic acid–mediated reductions in the expression of the respective structural genes (i.e., fnbA, fnbB, and hla). Thus, for the fibronectin-binding phenotype, salicylic acid–mediated reduction in binding can clearly be linked to a negative impact on the fnbA and/or fnbB genes. However, the reduction in overall binding of S. aureus to fibrinogen likely relates to a multifactorial impact of salicylic acid. For example, the expression of ClfA (a principal fibrinogen adhesin) can be upregulated by sigB (36). Therefore, salicylic acid could potentially either reduce or increase ClfA expression, depending on the growth phase. Moreover, the fibronectin-binding adhesin FnBα can mediate binding to fibrinogen as well as fibronectin (37). Finally, there are other fibrinogen-binding adhesins (e.g., Coa, C1fB) that could also be influenced by salicylic acid treatment. Therefore, the net mitigating effect of salicylic acid on S. aureus binding to fibrinogen is likely to reflect the composite impact on sarA, fnbA, and/or fnbB expression.

In addition to the suppression of matrix protein binding and cytolytic profiles, enhanced exoenzyme and protein A production was observed in the presence of salicylic acid. These pleiotropic phenotypic findings raised the likelihood that salicylic acid executed its antimicrobial effects through one or more global regulatory networks rather than a decrease in general gene transcription. We focused our investigations on three global regulators, sarA, agr, and sigB, since they have each been shown to impact one or more of the above phenotypes and have been implicated in vivo virulence, including in infective endocarditis (19, 38).
In *S. aureus*, the global regulatory element *sarA* upregulates the expression of a number of matrix adhesin genes (e.g., *fnbA*) and exotoxin genes (e.g., *hla*), while downregulating certain enzyme genes (e.g., serine protease [*spa*] and lipase [*geh*]) and protein A production (*spa*) (13, 14). The *sarA* locus is also involved in maximizing activation of the *agr* operon, an additional key global regulatory locus of *S. aureus*, which is particularly involved in α-hemolysin production (e.g., via *hla*) (39, 40). Transcriptional analysis indicates that the *sarA* locus is composed of three overlapping transcripts, designated *sarA* P1, *sarA* P3, and *sarA* P2 (41), all encoding the 14.5-kDa SarA protein, the major effector molecule of this locus. Recognizing that differential *sarA* promoter activation may modulate SarA expression, we explored the effects of salicylic acid on both the individual *sarA* promoters and the entire *sarA* operon, and also on the promoters of *agr* RNAII and RNAIII. Northern analysis, fluorometry, and flow cytometry studies demonstrated a salicylic acid–induced suppression of the *sarA* P1 promoter and of expression of the intact *sarA* P2-P3-P1 promoter complex, with a concomitant upregulation of the *sarA* P3 promoter. As the *sarA* P1 promoter is the strongest promoter of the *sarA* locus, this salicylic acid–mediated diminution in its activation correlates well with mitigation of *sarA*-dependent phenotypes (e.g., adhesin and α-hemolysin functions).

Our immunoblot studies disclosed a 10% salicylic acid–mediated reduction in SarA protein expression, consistent with the key role of the *sarA* locus in this context. The salicylic acid–mediated decrease in SarA protein levels was smaller than the reduction in *sarA* P1 promoter expression, by transcriptional fusion analyses. These data are concordant with the relative insensitivity of the immunoblot to detect modest differences in gene expression.

Additionally, our in vivo data underscored the significance of *sarA* in mediating salicylic acid–induced antivirulence effects. Importantly, we showed a suppression of *sarA* P1 promoter activity in animals with infective endocarditis treated with aspirin. Moreover, treatment of animals with salicylic acid reduced several key parameters of disease severity (e.g., vegetation weights, and vegetation and renal bacterial densities) in experimental infective endocarditis caused by the parental strain, but not in that caused by an isogenic *sarA* knockout construct. The inverse relationship between the *sarA* P1 and the *sarA* P3 promoter effects in the presence of salicylic acid (i.e., decreased *sarA* P1 transcription and increased *sarA* P3 transcription) fits the current paradigm of *sarA* regulation. Thus, activation of the otherwise quiescent *sarA* P3 promoter upstream may interfere with activation of the proximal but stronger *sarA* P1 promoter. This mechanism is thought to occur either by promoter occlusion or by the binding of a repressor protein between the *sarA* P1 and the *sarA* P3 promoter (28, 41). These findings provided important clues that the overall antistaphylococcal effect of salicylic acid is likely executed via additional regulatory elements that upregulate the *sarA* P3 promoter (e.g., *sigB*) (15, 16). Although the above data clearly implicate *sarA* in mediation of the salutary impacts of salicylic acid in vivo, we cannot precisely quantify the potential contributions of a large cadre of responsive downstream structural genes in this context.

The salicylic acid–induced suppression of *sarA* was accompanied by a reduction in *agr* RNAII and *agr* RNAIII promoter expression. It has previously been shown that *sarA* has binding specificity for the P2 and P3 interpromoter region of *agr*, thereby activating RNAII and RNAIII transcription (40). Therefore, downregulation of the *agr* promoters might either constitute a direct salicylic acid–induced effect on the *agr* locus, or be indirectly mediated via suppression of the *sarA* locus. Similarly, salicylic acid–mediated reduction in α-hemolysin production might be multimodal, i.e., via suppression of *agr*-dependent or *sarA*-dependent pathways, since the *bla* promoter is activated in response to both signals (42).

It should be noted that *S. aureus* virulence parameters in vitro (e.g., matrix protein adhesion and cytolsins) were not completely suppressed by salicylic acid but were reduced, in a drug concentration–dependent manner, by a maximum of approximately 50%. This finding correlates with the relative extents of *sarA* P1 and P2-P3-P1 promoter suppression, and concomitant *sarA* P3 promoter activation by both Northern and fluorometric analyses. It should also be emphasized that, in vivo, tissue bacterial densities were reduced by approximately 1 log<sub>10</sub> CFUs/g in untreated animals infected with an *S. aureus* *sarA* mutant; in contrast, salicylic acid treatment in animals infected with its *sarA*-intact parent strain yielded approximately 2 log<sub>10</sub> CFUs/g decrease in tissue bacterial densities. These findings suggest that *sarA*-independent and/or *sarA*-coregulated pathways are likely involved in salicylic acid–induced suppression of in vivo and in vitro virulence parameters. This notion is supported by: (a) the presence of at least 16 two-component regulatory systems in *S. aureus*, one or more of which may be responsive to salicylic acid (43); (b) the burgeoning family of *sarA* homologs that impact *S. aureus* virulence determinants (43); and (c) the numerous (>100) *sarA*-regulated downstream genes in *S. aureus* (44). It is therefore not surprising that regulatory pathways other than *sarA* and *agr* would be involved in salicylic acid–induced impacts. Studies of the potential effects of salicylic acid on candidate *sarA* homologs are in progress in our laboratories. Finally, mechanisms other than global regulatory elements—for example, direct effects on downstream structural genes and their encoded gene products—might contribute to salicylic acid impacts on *S. aureus* virulence and cannot be excluded.

Alternative σ factors have been shown to contribute importantly to bacterial survival by regulating stress-response genes in response to environmental stimuli (e.g., pH, heat shock), growth phase–specific signals
SH1000, as well as in strain COL, a genetically dis-
tinctions emphasize that the effects of salicylic acid may
impact in vitro phenotypes and in vivo virulence
salicylic acid exposure yielded similar mitigating
acid–mediated
ever, a virtually identical degree of salicylic
is relatively deficient (but not absent) (45). How-
tion within
prising, since this strain carries a natural 11-bp dele-
activation of the
sigB operon which then stimulates the sigB-dependent
P3 promoter. In turn, sarA P1 promoter expression is
repressed, leading to downmodulation of sarA and the
ensuing agr activation. These events would be expected
to repress sarA-upregulatable genes (e.g., fnbA, fnbB,
bla), derepress sarA-downregulatable exoenzyme (e.g.,
lipase and protease) and protein A genes (e.g., spa), and
repress agr-upregulatable genes (e.g., hla).

The sigB operon of S. aureus consists of four genes,
rsbU, rsbV, rsbW, and sigB (45). Studies in Bacillus sub-
tilis indicate that rsbU is involved predominantly in
acid stress, while rsbV may mediate sigB activation in
response to other environmental stressors (e.g.,
drugs) (47). The ability of salicylic acid to activate sigB
and its downstream sigB-dependent promoters, sarA
P3 and aspP3, in strain RN6390 was somewhat surpris-
ing, since this strain carries a natural 11-bp dele-
tion within rsbU, leading, in vitro, to a state in which
sigB is relatively deficient (but not absent) (45). How-
ever, a virtually identical degree of salicylic acid–mediated sigB activation was found in SH1000,
the functional rsbU derivative of RN6390, and in
FDA486, a strain with an intact rsbU gene. Moreover,
salicylic acid exposure yielded similar mitigating impacts on in vitro phenotypes and in vivo virulence
events in strain RN6390 and its rsbU-repaired variant
SH1000, as well as in strain COL, a genetically dis-
tinct strain with an intact rsbU locus. These observa-
tions emphasize that the effects of salicylic acid may
be mediated via an rsbU-independent pathway with-
in the sigB operon, and that such pathways may vary
between distinct strains.

With the current widespread problem of multi-
 antimicrobial resistance in S. aureus, development of new
therapeutic agents that can mitigate the activation of
bacterial virulence genes required for initiating and
propagating infections is considered a high priority. In
this respect, the use of aspirin and salicylic acid
appears to reduce staphylococcal virulence, rather
than inducing bactericidal activity. Provided that a
favorable safety profile is established in therapeutic tri-
als of systemic S. aureus infection, aspirin may have the
potential to be an effective adjunctive agent in the
treatment of serious hospital- or community-acquired
S. aureus infections.

Acknowledgments
This work was supported by NIH grants AI-39108 (to A.S. Bayer), AI-39001 and AI-48031 (to M.R. Yeaman), and AI-37142 (to A.L. Cheung), by Deutsche Forschungs-
gemeinschaft grant KU1155/1-1 (to L.I. Kupferwasser),
and by a research Grant-in-Aid from the Western
States Affiliate of the American Heart Association
(01S0699Y to A.S. Bayer).

1. Brumfitt, W., and Hamilton-Miller, J. 1989. Methicillin-resistant Staph-
ial virulence genes that are specifically induced in host tissues. Science. 259:688–688.
7. Birko, V., Velazquez, A., Yang, L., Yang, Y.C., and Barik, S. 1997. Trans-
criptional induction of multiple cytokines by human respiratory syn-
cytial virus requires activation of NF-kappa B and is inhibited by sodi-
11. Needs, C.J., and Brooks, P.M. 1985. Clinical pharmacokinetics of the sal-
12. Karlsson, A., Saravia-Otten, P., Tegmark, K., Morfeldt, E., and Arvidson,
S. 2001. Decreased amounts of cell wall-associated protein A and fibronectin-binding proteins in Staphylococcus aureus sarA mutants due to
of Staphylococcus aureus, a gene required for the expression of agr. J. Bacteri-
ol. 176:4168–4172.
sis of different promoters in the sar locus in Staphylococcus aureus. J. Bacte-
riol. 180:3828–3836.


